July 23, 2025

HER2DX Assay and Survival Outcomes in HER2-Positive Breast Cancer

In an individual patient-level meta-analysis reported in The Lancet Oncology, Villacampa et al found that the HER2DX assay risk score was prognostic for event-free survival outcomes in patients with e...

The ASCO Post

March 10, 2023

Four Leading UPMC/Pitt Scientists Receive Funding for Research in Breast Cancer

UMPC Hillman Cancer Center researchers receive significant funding from the Breast Cancer Research Foundation to support investigations aiming to improve cancer screening and enhance HER2 therapy.

The ASCO Post

January 25, 2023

SERENA-2 Trial: Camizestrant Improves Progression-Free Survival in Advanced Breast Cancer

The oral selective estrogen receptor degrader (SERD) camizestrant improved progression-free survival, as compared with fulvestrant, in previously treated postmenopausal women with advanced breast canc...

The ASCO Post

February 17, 2023

Association of Anthracycline Use With Risk of Congestive Heart Failure Among Patients Treated for Breast Cancer or Lymphoma

In a retrospective, population-based, case-control study reported in JAMA Network Open, Larsen et al found that patients receiving anthracyclines for breast cancer or lymphoma were at a significantly ...

The ASCO Post

February 06, 2023

WHO Launches New Roadmap on Breast Cancer

The World Health Organization (WHO) has released a new Global Breast Cancer Initiative Framework, providing a roadmap to attain targets to save 2.5 million lives from breast cancer by 2040. The new fr...

The ASCO Post

July 17, 2023

Regional Nodal Irradiation and Locoregional Recurrence in Patients With Favorable-Risk Node-Positive Breast Cancer

In a secondary analysis from the SWOG S1007 trial reported in JAMA Oncology, Reshma Jagsi, MD, DPhil, and colleagues found low rates of locoregional recurrence irrespective of the use of regional noda...

The ASCO Post

October 17, 2023

Can Younger Women With Hormone Receptor–Positive Breast Cancer Safely Pause Endocrine Therapy to Pursue Pregnancy?

Preserving fertility is a driving concern for many young women with breast cancer. Many of these women have hormone receptor–positive breast cancer and are treated with adjuvant endocrine therapy for ...

The ASCO Post

March 27, 2024

Intravenous Cetirizine Premedication to Mitigate Infusion-Related Reactions

Discover how a 62-year-old woman's paradoxical reaction during paclitaxel chemotherapy led to a substitution of intravenous diphenhydramine with intravenous cetirizine, highlighting the complexities of managing infusion-related reactions.

JADPRO

January 06, 2025

Risk-Reducing Surgeries Improve Survival for Younger Patients With Breast Cancer Who Are BRCA Carriers, Study Finds

Patients with early-onset breast cancer (aged 40 or younger at diagnosis) who have BRCA1 and/or BRCA2 pathogenic or likely pathogenic variants had improved overall survival by undergoing risk-reducing...

The ASCO Post